Article

Segment 7: Guidelines for Diagnostic Test Use

The panelists discuss guidelines for diagnostic test use and the biggest challenge from a payer standpoint.

Francisco J. Esteva, MD, PhD, and Daniel F. Hayes, MD, discuss guidelines for diagnostic test use from the National Comprehensive Cancer Network and the American Society of Clinical Oncology and the differences in how each organization approached the development of guidelines.

John L. Fox, MD, added that the biggest challenges with guidelines are the underuse and overuse of diagnostics—the former being a larger issue than the latter. From a payer vantage, tests that are well validated and have clinical utility should be done and they are willing to pay because the high cost of patients receiving an inappropriate therapy is an avoidable expense.

“So we’re encouraging testing and making sure that patients are appropriate for therapy,” he said.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP)
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Cathy Eng, MD, FACP, FASCO
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo